Tedizolid (TR-701): a new oxazolidinone with enhanced potency

Bibliography

• Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988;319:157-61
   PubMed Web of Science ®Google Scholar
• Uttley AH, George RC, Naidoo J, High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol Infect 1989;103:173-81
   PubMed Web of Science ®Google Scholar
• Colak D, Naas T, Gunseren F, First outbreak of vancomycin-resistant enterococci in a tertiary hospital in Turkey. J Antimicrob Chemother 2002;50:397-401
   PubMed Web of Science ®Google Scholar
• Hsueh PR, Teng LJ, Pan HJ, Emergence of vancomycin-resistant enterococci at a university hospital in Taiwan: persistence of multiple species and multiple clones. Infect Control Hosp Epidemiol 1999;20:828-33
   PubMed Web of Science ®Google Scholar
• Ramsey AM, Zilberberg MD. Secular trends of hospitalization with vancomycin-resistant enterococcus infection in the United States, 2000-2006. Infect Control Hosp Epidemiol 2009;30:184-6
   PubMed Web of Science ®Google Scholar
• National Nosocomial Infections Surveillance (NNIS) System Report, Data summary from January 1992-June 2001, issued August 2001. Am J Infect Control 2001;29:404-21
   PubMed Web of Science ®Google Scholar
• Fluit AC, Wielders CL, Verhoef J, Schmitz FJ. Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study. J Clin Microbiol 2001;39:3727-32
   PubMed Web of Science ®Google Scholar
• Voss A, Milatovic D, Wallrauch-Schwarz C, Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994;13:50-5
   PubMed Web of Science ®Google Scholar
• Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis 2005;5:275-86
   PubMed Web of Science ®Google Scholar
• Fridkin SK, Hageman JC, Morrison M, Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005;352:1436-44
   PubMed Web of Science ®Google Scholar
• Chang S, Sievert DM, Hageman JC, Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003;348:1342-7
   PubMed Web of Science ®Google Scholar
• Hiramatsu K, Hanaki H, Ino T, Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-6
   PubMed Web of Science ®Google Scholar
• Sanchez Garcia M, De la Torre MA, Morales G, Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010;303:2260-4
   PubMed Web of Science ®Google Scholar
• Jacobson LM, Milstone AM, Zenilman J, Daptomycin therapy failure in an adolescent with methicillin-resistant Staphylococcus aureus bacteremia. Pediatr Infect Dis J 2009;28:445-7
   PubMed Web of Science ®Google Scholar
• Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2005;40:1058-60
   PubMed Web of Science ®Google Scholar
• van Hal SJ, Paterson DL, Gosbell IB. Emergence of daptomycin resistance following vancomycin-unresponsive staphylococcus aureus bacteraemia in a daptomycin-naive patient – a review of the literature. Eur J Clin Microbiol Infect Dis 2011;30:603-10
   PubMed Web of Science ®Google Scholar
• Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of vancomycin. Antimicrob Agents Chemother 1998;42:1303-4
   PubMed Web of Science ®Google Scholar
• Moise PA, Schentag JJ. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents 2000;16(Suppl 1):S31-4
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Moise-Broder PA, Schentag J, Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-402
   PubMed Web of Science ®Google Scholar
• Gould IM. Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus. Int J Antimicrob Agents 2008;31(Suppl(2):1-9
   PubMed Web of Science ®Google Scholar
• Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990;34:1227-31
   PubMed Web of Science ®Google Scholar
• Woods CW, Cheng AC, Fowler VG Jr, Endocarditis caused by staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 2004;38:1188-91
   PubMed Web of Science ®Google Scholar
• Vara Prasad JV. New oxazolidinones. Curr Opin Microbiol 2007;10:454-60
   PubMed Web of Science ®Google Scholar
• Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003;138:135-42
   PubMed Web of Science ®Google Scholar
• Colca JR, McDonald WG, Waldon DJ, Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics. J Biol Chem 2003;278:21972-9
   PubMed Web of Science ®Google Scholar
• Betriu C, Morales G, Rodriguez-Avial I, Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain. Antimicrob Agents Chemother 2010;54:2212-15
   PubMed Web of Science ®Google Scholar
• Brown SD, Traczewski MM. Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges. Antimicrob Agents Chemother 2010;54:2063-9
   PubMed Web of Science ®Google Scholar
• Schaadt R, Sweeney D, Shinabarger D, Zurenko G. In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. Antimicrob Agents Chemother 2009;53:3236-9
   PubMed Web of Science ®Google Scholar
• Yum JH, Choi SH, Yong D, Comparative in vitro activities of torezolid (DA-7157) against clinical isolates of aerobic and anaerobic bacteria in South Korea. Antimicrob Agents Chemother 2010;54:5381-6
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M, Woodford N. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci. J Antimicrob Chemother 2009;63:713-15
   PubMed Web of Science ®Google Scholar
• Jones RN, Moet GJ, Sader HS, TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens. J Antimicrob Chemother 2009;63:716-20
   PubMed Web of Science ®Google Scholar
• Shaw KJ, Poppe S, Schaadt R, In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother 2008;52:4442-7
   PubMed Web of Science ®Google Scholar
• Leach KL, Swaney SM, Colca JR, The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol Cell 2007;26:393-402
   PubMed Web of Science ®Google Scholar
• Rodriguez-Avial I, Culebras E, Betriu C, In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci. J Antimicrob Chemother 2012;67:167-9
   PubMed Web of Science ®Google Scholar
• Locke JB, Hilgers M, Shaw KJ. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob Agents Chemother 2009;53:5265-74
   PubMed Web of Science ®Google Scholar
• Yamaki J, Synold T, Wong-Beringer A. Antivirulence potential of TR-700 and clindamycin on clinical isolates of Staphylococcus aureus producing phenol-soluble modulins. Antimicrob Agents Chemother 2011;55:4432-5
   PubMed Web of Science ®Google Scholar
• Prokocimer P, Bien P, Surber J, Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2011;55:583-92
   PubMed Web of Science ®Google Scholar
• Louie A, Liu W, Kulawy R, Drusano GL. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrob Agents Chemother 2011;55:3453-60
   PubMed Web of Science ®Google Scholar
• Im WB, Choi SH, Park JY, Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent. Eur J Med Chem 2011;46:1027-39
   PubMed Web of Science ®Google Scholar
• Keel RA, Crandon JL, Nicolau DP. Pharmacokinetics and pulmonary disposition of tedizolid and linezolid in three murine models. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL; 2011
   Google Scholar
• Bien P, Prokocimer P, Munoz KA, Bethune C. Absolute bioavailability of TR-701 FA and pharmacokinetics after single and multiple dose intravenous administration in healthy adult subjects. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; Boston, MA; 2010
   Google Scholar
• Housman S, Pope JS, Russomanno J, Pulmonary disposition of tedizolid following once-daily oral 200 mg tedizolid phosphate in healthy adult volunteers. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL; 2011
   Google Scholar
• Lemaire S, Van Bambeke F, Appelbaum PC, Tulkens PM. Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines. J Antimicrob Chemother 2009;64:1035-43
   PubMed Web of Science ®Google Scholar
• Dreskin H, Boyea T, Barker J, An evaluation of the absorption, metabolism, and excretion of orally administered [14C]-TR-701 FA in healthy subjects. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL; 2011
   Google Scholar
• Prokocimer P, Bien P, Munoz KA, Aster R. Hematological effects of TR-701, linezolid and placebo administered for 21 days in healthy subjects. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Meeting of the Infectious Diseases Society of America; Washington, DC; 2008
   Google Scholar
• Munoz KA, Bien P, Prokocimer P. Assessment of the venous tolerability of torezolid phosphate infused via a peripheral catheter: a novel approach. 21st European Congress of Clinical Microbiology and Infectious Diseases; Milan, Italy; 2011
   Google Scholar
• Falagas ME, Manta KG, Ntziora F, Vardakas KZ. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother 2006;58:273-80
   PubMed Web of Science ®Google Scholar